Emergent BioSolutions (EBS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.38, -11.14% vs the prior close of $7.18.
- Volume 2.24M shares, 1.7x its 50-day average.
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
EBS slides 11.1% to $6.38. Closed at $6.38, -11.14% vs the prior close of $7.18. Day range $6.15–$6.73, opened at $6.64.
EBS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — EBS slides 11.1% to $6.38
- Closed at $6.38, -11.14% vs the prior close of $7.18. Day range $6.15–$6.73, opened at $6.64.
- Volume was 2.24M shares, 1.7x its 50-day average of 1.33M.
- Price is +4.8% vs its 50-day average ($6.09) and -23.4% vs its 200-day average ($8.33).
- 52-week range $4.36–$14.06; today's close sits at 21% of that range, 54.6% below the 52-week high.
Oct 15, 2026 — EBS jumps 3.9% to $7.18
- Closed at $7.18, +3.91% vs the prior close of $6.91. Day range $6.84–$7.23, opened at $6.96.
- Volume was 654.80K shares, 0.5x its 50-day average of 1.33M — lighter than usual.
- Price is +18.4% vs its 50-day average ($6.07) and -14.1% vs its 200-day average ($8.36).
- 52-week range $4.36–$14.06; today's close sits at 29% of that range, 48.9% below the 52-week high.
Oct 14, 2026 — EBS ends flat (+0.0%) to $6.91, 3 down days in a row
- Closed at $6.91, +0.00% vs the prior close of $6.91. Day range $6.81–$7.07, opened at $6.87.
- Volume was 761.10K shares, 0.6x its 50-day average of 1.32M — lighter than usual.
- Price is +13.8% vs its 50-day average ($6.07) and -17.6% vs its 200-day average ($8.38).
- 52-week range $4.36–$14.06; today's close sits at 26% of that range, 50.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — EBS dips 1.0% to $6.91
- Closed at $6.91, -1.00% vs the prior close of $6.98. Day range $6.85–$7.07, opened at $6.95.
- Volume was 576.00K shares, 0.4x its 50-day average of 1.32M — lighter than usual.
- Price is +13.5% vs its 50-day average ($6.09) and -17.8% vs its 200-day average ($8.41).
- 52-week range $4.36–$14.06; today's close sits at 26% of that range, 50.9% below the 52-week high.
Oct 12, 2026 — EBS dips 1.1% to $6.98
- Closed at $6.98, -1.13% vs the prior close of $7.06. Day range $6.95–$7.33, opened at $7.08.
- Volume was 951.00K shares, 0.7x its 50-day average of 1.31M.
- Price is +14.5% vs its 50-day average ($6.10) and -17.3% vs its 200-day average ($8.44).
- 52-week range $4.36–$14.06; today's close sits at 27% of that range, 50.4% below the 52-week high.
Oct 9, 2026 — EBS jumps 3.7% to $7.06
- Closed at $7.06, +3.67% vs the prior close of $6.81. Day range $6.60–$7.06, opened at $6.73.
- Volume was 848.30K shares, 0.7x its 50-day average of 1.30M.
- Price is +15.7% vs its 50-day average ($6.10) and -16.6% vs its 200-day average ($8.47).
- 52-week range $4.36–$14.06; today's close sits at 28% of that range, 49.8% below the 52-week high.
Oct 8, 2026 — EBS slides 3.7% to $6.81
- Closed at $6.81, -3.68% vs the prior close of $7.07. Day range $6.79–$7.01, opened at $7.01.
- Volume was 1.15M shares, 0.9x its 50-day average of 1.29M.
- Price is +11.5% vs its 50-day average ($6.11) and -19.8% vs its 200-day average ($8.49).
- 52-week range $4.36–$14.06; today's close sits at 25% of that range, 51.6% below the 52-week high.
Oct 7, 2026 — EBS rises 1.7% to $7.07
- Closed at $7.07, +1.73% vs the prior close of $6.95. Day range $6.84–$7.35, opened at $7.05.
- Volume was 1.23M shares, 1.0x its 50-day average of 1.28M.
- Price is +15.6% vs its 50-day average ($6.12) and -17.0% vs its 200-day average ($8.52).
- 52-week range $4.36–$14.06; today's close sits at 28% of that range, 49.7% below the 52-week high.
Oct 6, 2026 — EBS slides 4.0% to $6.95
- Closed at $6.95, -4.01% vs the prior close of $7.24. Day range $6.75–$7.27, opened at $7.16.
- Volume was 1.86M shares, 1.5x its 50-day average of 1.25M.
- Price is +13.5% vs its 50-day average ($6.12) and -18.7% vs its 200-day average ($8.55).
- 52-week range $4.36–$14.06; today's close sits at 27% of that range, 50.6% below the 52-week high.
Oct 5, 2026 — EBS jumps 14.4% to $7.24, a 1-month high on 1.9x normal volume
- Closed at $7.24, +14.38% vs the prior close of $6.33. Day range $6.45–$7.65, opened at $6.53.
- Volume was 2.34M shares, 1.9x its 50-day average of 1.22M — unusually heavy trading.
- Price is +18.1% vs its 50-day average ($6.13) and -15.6% vs its 200-day average ($8.57).
- 52-week range $4.36–$14.06; today's close sits at 30% of that range, 48.5% below the 52-week high.
Oct 2, 2026 — EBS dips 0.6% to $6.33, 3 down days in a row
- Closed at $6.33, -0.63% vs the prior close of $6.37. Day range $6.24–$6.41, opened at $6.41.
- Volume was 614.50K shares, 0.5x its 50-day average of 1.22M — lighter than usual.
- Price is +3.3% vs its 50-day average ($6.13) and -26.4% vs its 200-day average ($8.60).
- 52-week range $4.36–$14.06; today's close sits at 20% of that range, 55.0% below the 52-week high.
- That makes 3 straight losses.
EBS latest news & SEC filings
Every SEC filing by or about EBS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 7, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Degolyer Donald W sold 17,800 shares at $7.09 (≈$126.20K) on Oct 7, 2026; now holds 111,921
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Williams Paul Anthony sold 3,000 shares at $6.53 (≈$19.59K) on Oct 1, 2026; now holds 156,098
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $234.30M (prior year $140.90M) (+66.3% vs Jun 30, 2025)
- Net income: -$180.20M (prior year -$12.00M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.49 (prior year -$0.22) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Williams Paul Anthony sold 3,000 shares at $8.40 (≈$25.20K) on Jul 1, 2026
- Williams Paul Anthony sold 3,000 shares at $8.40 (≈$25.20K) on Jul 1, 2026
- Williams Paul Anthony sold 3,000 shares at $8.40 (≈$25.20K) on Jul 1, 2026
- Williams Paul Anthony sold 3,000 shares at $8.40 (≈$25.20K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade EBS
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 26, 2026, Oct 29, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.26% (largest 14.4%). That is a volatile stock.
- Liquidity: about 1.07M shares (≈$6.85M) trade per day on average.
- 52-week position: $6.38 vs a range of $4.36–$14.06 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Paul Anthony Williams sold 3,000 shares on Jul 1, 2026.
- Latest filings: 8-K Oct 16, 2026; 8-K Sep 14, 2026; 8-K Sep 1, 2026.
- Share count: 51.27M shares outstanding (Jul 30, 2026), -3.9% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Pharmaceutical Preparations.
EBS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.64 | 6.73 | 6.15 | 6.38 | 2.24M |
| Oct 15, 2026 | 6.96 | 7.23 | 6.84 | 7.18 | 654.80K |
| Oct 14, 2026 | 6.87 | 7.07 | 6.81 | 6.91 | 761.10K |
| Oct 13, 2026 | 6.95 | 7.07 | 6.85 | 6.91 | 576.00K |
| Oct 12, 2026 | 7.08 | 7.33 | 6.95 | 6.98 | 951.00K |
| Oct 9, 2026 | 6.73 | 7.06 | 6.60 | 7.06 | 848.30K |
| Oct 8, 2026 | 7.01 | 7.01 | 6.79 | 6.81 | 1.15M |
| Oct 7, 2026 | 7.05 | 7.35 | 6.84 | 7.07 | 1.23M |
| Oct 6, 2026 | 7.16 | 7.27 | 6.75 | 6.95 | 1.86M |
| Oct 5, 2026 | 6.53 | 7.65 | 6.45 | 7.24 | 2.34M |
| Oct 2, 2026 | 6.41 | 6.41 | 6.24 | 6.33 | 614.50K |
| Oct 1, 2026 | 6.56 | 6.56 | 6.29 | 6.37 | 811.20K |
| Sep 30, 2026 | 6.88 | 6.88 | 6.56 | 6.60 | 760.60K |
| Sep 29, 2026 | 6.82 | 7.00 | 6.75 | 6.92 | 745.00K |
| Sep 28, 2026 | 6.75 | 6.95 | 6.60 | 6.86 | 682.90K |
| Sep 25, 2026 | 6.79 | 6.85 | 6.67 | 6.79 | 631.40K |
| Sep 24, 2026 | 6.60 | 6.87 | 6.56 | 6.77 | 914.30K |
| Sep 23, 2026 | 6.73 | 6.86 | 6.58 | 6.67 | 1.06M |
| Sep 22, 2026 | 6.61 | 6.89 | 6.54 | 6.76 | 1.14M |
| Sep 21, 2026 | 6.80 | 6.90 | 6.48 | 6.55 | 1.51M |
About Emergent BioSolutions
Emergent BioSolutions (EBS) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in GAITHERSBURG, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1367644.
EBS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sujata Tyagi Dayal | Director | May 4, 2026 |
| Donald W Degolyer | Director | May 4, 2026 |
| John D Jr Fowler | Director | May 4, 2026 |
| Neal Franklin Fowler | Director | May 4, 2026 |
| Zsolt Harsanyi | Chairman | May 4, 2026 |
| Keith Katkin | Director | May 4, 2026 |
| Joseph C Papa | President and CEO | May 1, 2026 |
| Ronald Richard | Director | May 4, 2026 |
| Marvin L White | Director | May 4, 2026 |
| Kathryn C Zoon | Director | May 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Stephanie Duatschek | EVP, CGO | Aug 12, 2026 |
| Coleen Glessner | EVP, Quality & Ethics, and CPL | Jun 10, 2026 |
| Zsolt Harsanyi | Chairman | May 4, 2026 |
| William Hartzel | SVP, Bioservices | Jun 10, 2026 |
| Richard S Lindahl | EVP, Chief Financial Officer | Jun 10, 2026 |
| Simon C Lowry | SVP, R&D, CMO | May 1, 2026 |
| Joseph C Papa | President and CEO | May 1, 2026 |
| Jessica Perl | SVP, General Counsel, Corp Sec | May 1, 2026 |
| Paul Anthony Williams | SVP, Products Business | Jul 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Paul Anthony Williams | Sale | 3,000 | $8.40 |
| Jul 1, 2026 | Paul Anthony Williams | Sale | 3,000 | $8.40 |
| Jul 1, 2026 | Paul Anthony Williams | Sale | 3,000 | $8.40 |
| Jul 1, 2026 | Paul Anthony Williams | Sale | 3,000 | $8.40 |
| May 1, 2026 | Kathryn C Zoon | Sale | 1,057 | $8.97 |
| May 1, 2026 | Kathryn C Zoon | Sale | 16,145 | $8.36 |
| May 1, 2026 | Kathryn C Zoon | Sale | 1,057 | $8.97 |
| May 1, 2026 | Kathryn C Zoon | Sale | 16,145 | $8.36 |
| May 1, 2026 | Kathryn C Zoon | Sale | 1,057 | $8.97 |
| May 1, 2026 | Kathryn C Zoon | Sale | 16,145 | $8.36 |
| May 1, 2026 | Kathryn C Zoon | Sale | 1,057 | $8.97 |
| May 1, 2026 | Kathryn C Zoon | Sale | 16,145 | $8.36 |
| May 1, 2026 | Donald W Degolyer | Sale | 954 | $8.96 |
| May 1, 2026 | Donald W Degolyer | Sale | 14,527 | $8.36 |
| May 1, 2026 | Donald W Degolyer | Sale | 954 | $8.96 |
EBS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $742.90M | $52.60M | 0.93 | $170.60M |
| Dec 31, 2024 | $1.04B | $-190.60M | -3.60 | $58.70M |
| Dec 31, 2023 | $1.05B | $-760.50M | -14.85 | $-206.30M |
| Dec 31, 2022 | — | $-211.60M | -4.22 | $-34.10M |
| Dec 31, 2021 | — | $219.50M | 4.06 | $320.20M |
Latest balance sheet: total assets $1.12B, total liabilities $775.40M, cash $139.70M (as of Jun 30, 2026).
EBS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $7.54 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $8.23 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $11.10 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $9.40 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $6.03 |
| May 7, 2025 | 8-K Item 2.02 (results) | $4.74 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $6.83 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $9.20 |
| Oct 2, 2024 | 8-K Item 2.02 (results) | — |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Mar 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EBS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.